|
Synonyms: Ogsiveo® | PF-03084014 | PF3084014 | Z-3181
nirogacestat is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Nirogacestat (PF-3084014) is compound 14f in [2] where it is described as a centrally active γ-secretase inhibitor. It is a reversible, non-competitive, and orally bioactive agent. The compound prevents proteolytic cleavage of the Notch receptor and release of the oncogenic Notch intracellular domain fragment. This disrupts downstream pathway signalling via all 4 human Notch receptors and leads to cell cycle arrest and apoptosis in tumour cells [1,3,8,11,11-12]. Nirogacestat binds directly within the catalytic substrate-binding pocket of the presenilin 1 (PSEN1) γ secretase subunit.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| This compound was assessed in clinical trials for the treatment of several types of cancer. Click here to view the full list of PF-03084014 trials registered with ClinicalTrials.gov. A number of PF-03084014 clinical trials appear to have been stopped or withdrawn, apparently for business reasons. Notes against these trials state that there were no safety/efficacy concerns behind the decisions. Development for desmoid tumours [9] (a rare and aggressive soft tissue sarcoma) was continued by SpringWorks Therapeutics. There were no FDA-approved treatments for desmoid tumours at the time. Based on efficacy data coming from clinical trials [10], nirogacestat was granted FDA orphan designation for this indication in mid-2018. EMA orphan drug designation followed in late 2019. In 2023, the FDA accepted nirogacestat for priority review as a treatment option for locally invasive, soft tissue desmoid tumours, and this culminated in full approval in November of that year [6-7]. Nirogacestat (Ogsiveo) was the first γ-secretase inhibitor to reach the clinic and was the first approved treatment for desmoid tumours. In October 2026 the UK's National Institute for Health and Care Excellence (NICE) recommended nirogacestat for use in the NHS, as an option to treat progressing desmoid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04195399 | A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery | Phase 2 Interventional | Children's Oncology Group | ||
| NCT01981551 | Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis | Phase 2 Interventional | National Institutes of Health Clinical Center (CC) | ||
| NCT03785964 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Phase 3 Interventional | SpringWorks Therapeutics, Inc. | 4-5 | |
| NCT05348356 | Nirogacestat in Ovarian Granulosa Cell Tumors | Phase 2 Interventional | SpringWorks Therapeutics, Inc. | ||